enGene to Participate in Upcoming Investor Conferences
enGene Therapeutics (ENGN) announced that management will participate in investor conference fireside chats on November 16 and November 19, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
UBS Global Biopharma Conference 2026
Date: Monday, November 16, 2026
Time: 3:20 p.m. GMT / 10:20 a.m. ET
Format: Fireside Chat
Jefferies Global Healthcare Conference in
Date: Thursday, November 19, 2026
Time: 10:30 a.m. GMT / 5:30 a.m. ET
Format: Fireside Chat
A live webcast of these events can be accessed on the “Events and Presentations” page under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days.
About enGene
enGene Therapeutics Inc. is a clinical-stage biotechnology company mainstreaming non-viral genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease.
Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.
To learn more, please visit enGene.com and follow us on LinkedIn, X and BlueSky.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261106948854/en/
Media and Investor Contact:
Lauren Hopfer
Lhopfer@engene.com
Source: enGene Therapeutics Inc.